Monoclonal antibodies for the treatment of non-hematological tumors: a safety review
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 17, Issue 12, Pages 1197-1209
Publisher
Informa UK Limited
Online
2018-11-21
DOI
10.1080/14740338.2018.1550068
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
- (2018) Giuseppe Badalamenti et al. CELLULAR IMMUNOLOGY
- Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis
- (2018) Fausto Petrelli et al. ONCOLOGY
- Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
- (2018) Claudia De Lorenzo et al. OncoTargets and Therapy
- Ipilimumab in the Treatment of Metastatic Melanoma: A Summary of Recent Studies
- (2018) Paolo A Ascierto TUMORI
- Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients
- (2018) Mariana L. Henry et al. JACC-Cardiovascular Imaging
- Immune Checkpoint Inhibitor Toxicity
- (2018) David J. Palmieri et al. Current Oncology Reports
- New and emerging concepts in the use of denosumab for the treatment of osteoporosis
- (2018) E. Michael Lewiecki Therapeutic Advances in Musculoskeletal Disease
- Targeting Immune Checkpoints in Cancer Therapy
- (2017) Suzanne L. Topalian JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials
- (2017) Manni Wang et al. Drug Design Development and Therapy
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
- (2017) Hyun Tae Lee et al. Scientific Reports
- Circulating Tumor Markers: Harmonizing the yin and yang of CTCs and ctDNA for precision medicine
- (2016) I. S. Batth et al. ANNALS OF ONCOLOGY
- Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures
- (2016) Kenneth Pittman et al. Asia-Pacific Journal of Clinical Oncology
- Management of Epidermal Growth Factor Receptor Inhibitor-Induced Hypomagnesemia: A Systematic Review
- (2016) Di (Maria) Jiang et al. Clinical Colorectal Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
- (2016) Gennaro Riccio et al. Human Vaccines & Immunotherapeutics
- Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
- (2016) Helena Verdaguer et al. Therapeutic Advances in Medical Oncology
- Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis
- (2016) Prakirthi Yerram et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Ramucirumab: A Review in Advanced Gastric Cancer
- (2015) Sarah L. Greig et al. BIODRUGS
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials
- (2015) Marco Miroddi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer
- (2015) Louisa Lo et al. Expert Opinion on Drug Metabolism & Toxicology
- New clinical advances in immunotherapy for the treatment of solid tumours
- (2015) Valentina A. Zavala et al. IMMUNOLOGY
- Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer
- (2015) Stefania Mantarro et al. Internal and Emergency Medicine
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Practical Management of Bevacizumab-Related Toxicities in Glioblastoma
- (2015) A. A. Brandes et al. ONCOLOGIST
- Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
- (2015) Alison T. Stopeck et al. SUPPORTIVE CARE IN CANCER
- Value of bevacizumab in treatment of colorectal cancer: A meta-analysis
- (2015) Chun-Ying Qu WORLD JOURNAL OF GASTROENTEROLOGY
- Targeting the tumor microenvironment to enhance antitumor immune responses
- (2015) Kevin Van der Jeught et al. Oncotarget
- Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
- (2015) Jiabei He et al. Scientific Reports
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
- (2014) J. Y. Douillard et al. ANNALS OF ONCOLOGY
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
- (2014) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario
- (2014) Giuseppe Bronte et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Panitumumab safety for treating colorectal cancer
- (2014) Stefan Stremitzer et al. Expert Opinion On Drug Safety
- Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment
- (2014) Chiara Camisaschi et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Trastuzumab Administration in Patients with Metastatic Breast Cancer – Experience of a Large University Breast Center
- (2014) A. Hartkopf et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive, Locally Advanced, or Metastatic Breast Cancer
- (2014) Kathy D. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Ipilimumab in the treatment of metastatic melanoma: management of adverse events
- (2014) Giuseppina Della Vittoria Scarpati et al. OncoTargets and Therapy
- The role of targeted therapy for gastrointestinal tumors
- (2014) Christian Rolfo et al. Expert Review of Gastroenterology & Hepatology
- Cardiotoxicity of novel HER2-targeted therapies
- (2013) Mehmet A.N. Sendur et al. CURRENT MEDICAL RESEARCH AND OPINION
- Monoclonal antibodies in gastrointestinal cancers
- (2013) Giuseppe Bronte et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is There a Role for Bevacizumab in the Treatment of Glioblastoma?
- (2013) A. S. Chi et al. ONCOLOGIST
- Biological Drugs: Classic Adverse Effects and New Clinical Evidences
- (2012) Paolo Della Pina et al. Cardiovascular Toxicology
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
- (2012) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
- (2011) J.M. Baas et al. CANCER TREATMENT REVIEWS
- Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies
- (2011) Fausto Petrelli et al. Expert Opinion On Drug Safety
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
- (2011) Paolo A Ascierto et al. Journal of Translational Medicine
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab
- (2011) A. H. Boekhout et al. ONCOLOGIST
- Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion
- (2011) Guenther G. Steger et al. Therapeutic Advances in Medical Oncology
- Inflammatory cytokines as a third signal for T cell activation
- (2010) Julie M Curtsinger et al. CURRENT OPINION IN IMMUNOLOGY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients
- (2010) S. Wu et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
- (2010) Michael L. Maitland et al. JNCI-Journal of the National Cancer Institute
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Review on Bevacizumab and Surgical Wound Healing
- (2009) Chad R. Gordon et al. ANNALS OF PLASTIC SURGERY
- Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury
- (2009) Kevin Bersell et al. CELL
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
- (2009) M. Kozloff et al. ONCOLOGIST
- Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer
- (2008) M. PEETERS et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens
- (2008) R. M. Giusti et al. CLINICAL CANCER RESEARCH
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of Vascular Endothelial Growth Factor in Wound Healing
- (2008) Philip Bao et al. JOURNAL OF SURGICAL RESEARCH
- Clinical Consequences and Management of Hypomagnesemia
- (2008) K. J. Martin et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
- (2008) J. D. Wolchok et al. ONCOLOGIST
- Epidermal Growth Factor Receptor Monoclonal Antibodies for the Treatment of Metastatic Colorectal Cancer
- (2008) Gary W Jean et al. PHARMACOTHERAPY
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started